Imprimis Pharmaceuticals is a pharmaceutical company dedicated to delivering high quality and innovative medicines to physicians and patients at accessible prices. The Company operates through the business of developing drug therapies and providing such therapies through sterile and non-sterile pharmaceutical compounding services segment. Imprimis, through its Imprimis Cares program, owns, markets and dispenses a portfolio of compounded therapeutic in several therapeutic areas, including ophthalmology, urology, otolaryngology and infectious diseases.

Type
Public
HQ
San Diego, US
Founded
2012
Size (employees)
56 (est)
Imprimis Pharmaceuticals was founded in 2012 and is headquartered in San Diego, US
Report incorrect company information

Key People/Management at Imprimis Pharmaceuticals

Mark L. Baum J.D

Mark L. Baum J.D

Chief Executive Officer, Member, Board of Directors
CFA Andrew R. Boll CMA

CFA Andrew R. Boll CMA

Chief Financial Officer
John Saharek

John Saharek

Chief Commercial Officer
Pramod Sharma

Pramod Sharma

Vice President, Quality
Sanjay Samudre

Sanjay Samudre

Vice President, Manufacturing
David Moufarrege

David Moufarrege

Vice President, Technology
Show more

Imprimis Pharmaceuticals Office Locations

Imprimis Pharmaceuticals has offices in Roxbury Township, Irvine and San Diego
San Diego, US (HQ)
350 12264 El Camino Real
Irvine, US
9257 Research Dr
Roxbury Township, US
6b 1705 US-46
Show all (3)
Report incorrect company information

Imprimis Pharmaceuticals Financials and Metrics

Imprimis Pharmaceuticals Financials

Imprimis Pharmaceuticals's revenue was reported to be $19.94 m in FY, 2016 which is a 105.2% increase from the previous period.
USD

Revenue (Q1, 2018)

8.9 m

Gross profit (Q1, 2018)

4.8 m

Gross profit margin (Q1, 2018), %

54.1%

Net income (Q1, 2018)

(3.5 m)

EBIT (Q1, 2018)

(1.8 m)

Market capitalization (25-May-2018)

45.9 m

Closing share price (25-May-2018)

2.2
Imprimis Pharmaceuticals's current market capitalization is $45.9 m.
Annual
USDFY, 2014FY, 2015FY, 2016

Revenue

1.7 m9.7 m19.9 m

Revenue growth, %

485%105%

Cost of goods sold

1.1 m5.2 m9.8 m

Gross profit

567.4 k4.5 m10.1 m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018

Revenue

667.7 k441 k1.6 m2 m2.7 m4.4 m4.9 m4.9 m6.1 m6.9 m6.5 m8.9 m

Cost of goods sold

239 k1 m1.1 m1.2 m2.2 m2.2 m2.3 m3.4 m3.3 m3.4 m4.1 m

Gross profit

202.1 k556 k917 k1.5 m2.1 m2.7 m2.5 m2.7 m3.6 m3.1 m4.8 m

Gross profit Margin, %

46%36%47%55%49%56%52%45%52%48%54%
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016

Cash

15.6 m8.2 m2.7 m8.9 m

Accounts Receivable

81.3 k840 k2.9 m

Inventories

105.1 k372.7 k1.4 m1.8 m

Current Assets

15.7 m9.1 m5.9 m14.8 m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017Q1, 2018

Cash

16.8 m14.2 m12.1 m10.4 m2.9 m10.1 m6.6 m11.8 m5.4 m2.4 m7.4 m4.2 m3.9 m

Accounts Receivable

1.4 k81.1 k68.3 k436 k579 k701 k943 k1.9 m2.2 m3 m2.9 m2.6 m1.5 m

Inventories

172.8 k351.2 k711 k793 k1.3 m1.2 m1.4 m1.9 m2 m1.8 m2.4 m2 m

Current Assets

17.4 m14.4 m12.8 m11.3 m4.6 m12 m9.4 m14.9 m9.4 m9 m13.6 m10.4 m10.1 m7.4 m
Annual
USDFY, 2013FY, 2014FY, 2015FY, 2016

Net Income

(7.6 m)(10.1 m)(15.9 m)(19.1 m)

Depreciation and Amortization

5.7 k

Inventories

(17 k)(159.5 k)(314 k)(429 k)

Accounts Payable

(239.8 k)345.4 k1 m1.5 m
Quarterly
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q1, 2018

Net Income

(2.1 m)(2.3 m)(2.6 m)(2.5 m)(3.1 m)(3.7 m)(4 m)(4.5 m)(4.6 m)(3.9 m)(5 m)(3.5 m)

Depreciation and Amortization

2.6 k

Inventories

172.8 k351.2 k711 k793 k1.3 m1.2 m1.4 m1.9 m2 m209 k

Accounts Payable

145.2 k750.1 k804.2 k1.1 m1.2 m1.9 m4.3 m4 m3.8 m3.9 m106 k
USDY, 2018

Revenue/Employee

158.3 k

Financial Leverage

255.4 x
Show all financial metrics
Report incorrect company information

Imprimis Pharmaceuticals News and Updates

Report incorrect company information